Gene editing is easily one of the most exciting areas in the biotech landscape right now. Promising to offer treatments for conditions previously written off as incurable, gene-editing technology has the potential not only to help millions of people get better but also to make billions in revenue for the companies working in this space.
While gene-editing treatments are still in the early stages of clinical testing, a handful of companies are considered front-runners in the emerging sector. Editas Medicine (NASDAQ: EDIT) is one of them. Although there are many reasons to be cautious when it comes to an early stage biotech stock like Editas, there are a number of reasons it could be a promising investment in a high-growth, high-risk portfolio.
Image source: Getty Images.
Source Fool.com